---
title: "Rallybio (RLYB) news: reverse merger and offering"
url: "https://aibio.space/companies/rallybio/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "RLYB reverse merger and offering news: Rallybio holders to own 2.8% of the combined company in Avenzo reverse merger."
---

RLYB Rallybio Corporation NASDAQ · United States

# Rallybio (RLYB) news RLYB reverse merger and offering news

Mergers · 2026-10-26

## [Rallybio declares estimated $82.7 million cash distribution tied to Avenzo merger](https://aibio.space/news/rallybio-declares-estimated-82-7-million-cash-distribution-tied-avenzo/)

Rallybio's board declared an estimated $13.56 per share special cash distribution on October 25, 2026. Payment is conditioned on stockholder approval at a November 4, 2026 meeting, with closing expected November 6, 2026.

## Latest Rallybio news

1. 2026-10-15 Mergers [Rallybio holders to own 2.8% of the combined company in Avenzo reverse merger](https://aibio.space/news/rallybio-holders-own-2-8-percent-combined-company-avenzo-reverse/) Rallybio's holders would keep 2.8% of the merged company, while Avenzo's holders would own 56.6% and investors in a $215.0 million financing 40.6%. Rallybio stockholders vote on the deal on November 4.
2. 2026-09-09 Company Updates [Rallybio CFO Jonathan Lieber moves to part-time employment](https://aibio.space/news/rallybio-cfo-jonathan-lieber-moves-part-time-employment/) Rallybio said Jonathan Lieber will move to part-time employment on September 15, 2026 and remain Chief Financial Officer. His employment ends at the closing of the pending Avenzo Therapeutics merger.
3. 2026-05-03 Mergers [Rallybio to receive $50,000,000 fee after Candid ends merger](https://aibio.space/news/rallybio-receive-50-000-000-fee-after-candid-ends-merger/) Candid terminated its merger agreement with Rallybio on May 3, 2026, and entered into a Permitted Alternative Agreement with UCB S.A. Rallybio intends to withdraw its Form S-4 registration statement.
4. 2025-08-29 Listings [Rallybio moves to Nasdaq Capital Market, gets 180 more days on bid price](https://aibio.space/news/rallybio-moves-nasdaq-capital-market-gets-180-more-days-bid-price/) Rallybio moved its listing to the Nasdaq Capital Market on August 29, 2025 after missing its first bid-price deadline. It received 180 more days, to February 23, 2026, to bring its stock back to at least $1.00.
5. 2025-07-08 Mergers [Rallybio sells 50% stake in ENPP1 joint venture to Recursion for cash and shares](https://aibio.space/news/rallybio-sells-50-percent-stake-enpp1-joint-venture-recursion-cash/) Recursion issued 1,457,952 of its shares to Rallybio's selling subsidiary. Rallybio could receive more shares, development milestone payments and low single digit royalties later.
6. 2025-07-08 Mergers [Rallybio sells ENPP1 joint venture stake to Recursion for initial $7,500,000 in stock](https://aibio.space/news/rallybio-sells-enpp1-joint-venture-stake-recursion-initial-7-500-000/) Rallybio sold its 50% interest in the ENPP1 joint venture to a Recursion subsidiary on July 8, 2025. It received 1,457,952 Recursion shares for an initial $7,500,000, and it could receive $12,500,000 more in stock if milestones are met.
7. 2025-03-13 Financings [Rallybio cuts at-the-market stock program to $9,550,000 from $100,000,000](https://aibio.space/news/rallybio-cuts-market-stock-program-9-550-000-100-000-000/) Rallybio cut its at-the-market stock program from $100,000,000 to $9,550,000 on March 13, 2025. The company says it has sold no shares under the agreement, and the cut follows an SEC rule that limits sales for companies with a public float below $75.0 million.
8. 2025-02-25 Listings [Rallybio gets Nasdaq minimum bid price notice, has until August 25, 2025](https://aibio.space/news/rallybio-gets-nasdaq-minimum-bid-price-notice-has-until-august-25-2025/) Rallybio's closing bid price was below $1.00 for 30 consecutive business days. It may be eligible for another 180-day period if it applies to move its listing to the Nasdaq Capital Market.

## Rallybio at a glance

- **Ticker**: RLYB

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Sep 30, 2026**: $90.7 million

### Related companies

- [OS Therapies](https://aibio.space/companies/os-therapies/) AMEX: OSTX
- [Cartesian Therapeutics](https://aibio.space/companies/cartesian-therapeutics/) NASDAQ: RNAC
- [ThermoGenesis Holdings](https://aibio.space/companies/thermogenesis/) OTC: THMO
- [Vor Biopharma](https://aibio.space/companies/vor-biopharma/) NASDAQ: VOR
- [Wave Life Sciences](https://aibio.space/companies/wave-life-sciences/) NASDAQ: WVE
- [Replimune Group](https://aibio.space/companies/replimune/) NASDAQ: REPL
- [PaxMedica](https://aibio.space/companies/paxmedica/) OTC: PXMD
- [Black Diamond Therapeutics](https://aibio.space/companies/black-diamond-therapeutics/) NASDAQ: BDTX

### Also on NASDAQ

- [Anavex Life Sciences](https://aibio.space/companies/anavex-life-sciences/) AVXL
- [Invivyd](https://aibio.space/companies/invivyd/) IVVD
- [Ovid Therapeutics](https://aibio.space/companies/ovid-therapeutics/) OVID
- [Scinai Immunotherapeutics](https://aibio.space/companies/scinai-immunotherapeutics/) SCNI
- [aTyr Pharma](https://aibio.space/companies/atyr-pharma/) ATYR
- [MYRIAD GENETICS INC](https://aibio.space/companies/myriad-genetics/) MYGN

## What Rallybio does

Rallybio Corporation is a clinical-stage biotechnology company focused on developing therapies for severe and rare diseases. Its lead program, RLYB116, is a once-weekly, small volume, subcutaneously injected inhibitor of complement component 5 (C5), intended for diseases of complement dysregulation. The company says it completed two Phase 1 trials in healthy participants and a confirmatory Phase 1 trial in 2025. RLYB332, a long-acting matriptase-2 antibody for diseases of iron overload, is in preclinical development. The text names paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, refractory generalized myasthenia gravis and neuromyelitis optica spectrum disorder as complement-related diseases with remaining need. On March 1, 2026, Rallybio entered into a merger agreement with Candid, a clinical-stage company advancing T-cell engager therapeutics for autoimmune diseases. A concurrent financing with an aggregate commitment of approximately $505.5 million is part of the transaction, and Rallybio's pre-merger assets, called Legacy Assets, are subject to a contingent value right. The company also cites a membership interest purchase agreement with Recursion Pharmaceuticals, Inc. dated July 8, 2025.

| Product or program | What it is | Stage |
|---|---|---|
| RLYB116 | Once-weekly subcutaneous C5 inhibitor for complement dysregulation diseases | two Phase 1 trials completed; confirmatory Phase 1 completed in 2025 |
| RLYB332 | Long-acting matriptase-2 antibody for diseases of iron overload | preclinical development |

Summarised from the company's [10-K filed Mar 16, 2026](https://www.sec.gov/Archives/edgar/data/1739410/000162828026018261/rlyb-20251231.htm).

## Rallybio annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | [$858,000](https://www.sec.gov/Archives/edgar/data/1739410/000162828026018261/) | [$636,000](https://www.sec.gov/Archives/edgar/data/1739410/000162828026018261/) |
| Research and development | [$19.6 million](https://www.sec.gov/Archives/edgar/data/1739410/000162828026018261/) | [$41.5 million](https://www.sec.gov/Archives/edgar/data/1739410/000162828026018261/) |
| Net income (loss) | [-$9.0 million](https://www.sec.gov/Archives/edgar/data/1739410/000162828026018261/) | [-$57.8 million](https://www.sec.gov/Archives/edgar/data/1739410/000162828026018261/) |
| Cash from operations | [-$29.8 million](https://www.sec.gov/Archives/edgar/data/1739410/000162828026018261/) | [-$49.3 million](https://www.sec.gov/Archives/edgar/data/1739410/000162828026018261/) |
| Cash and equivalents | [$31.4 million](https://www.sec.gov/Archives/edgar/data/1739410/000162828026067422/) | [$13.9 million](https://www.sec.gov/Archives/edgar/data/1739410/000162828026018261/) |
| Short-term investments | [$23.4 million](https://www.sec.gov/Archives/edgar/data/1739410/000162828026067422/) | [$51.6 million](https://www.sec.gov/Archives/edgar/data/1739410/000162828026018261/) |

Latest balance sheet, Sep 30, 2026 (10-Q): cash and equivalents $90.7 million, plus short-term investments of $0, $90.7 million in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about Rallybio

Is Rallybio doing a reverse merger?

Our latest story on this, dated Oct 15, 2026: "Rallybio holders to own 2.8% of the combined company in Avenzo reverse merger". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/rallybio-holders-own-2-8-percent-combined-company-avenzo-reverse/).

Has Rallybio raised money recently?

Our latest story on this, dated Mar 13, 2025: "Rallybio cuts at-the-market stock program to $9,550,000 from $100,000,000". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/rallybio-cuts-market-stock-program-9-550-000-100-000-000/).

What is the ticker symbol of Rallybio?

Rallybio Corporation trades under the ticker RLYB on NASDAQ.

Where is Rallybio listed?

Rallybio Corporation is listed on NASDAQ.

What is the SEC CIK of Rallybio?

The SEC Central Index Key (CIK) for Rallybio Corporation is 1739410. Its filings are on SEC EDGAR.

How many shares does Rallybio have outstanding?

5,310,499 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-06.

Which country or territory is Rallybio listed under?

Our directory records Rallybio Corporation under United States.

What does Rallybio do?

Our directory classifies Rallybio Corporation as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of Rallybio?

The ISIN recorded for Rallybio Corporation is US75120L2097.

Does aibio.space cover Rallybio?

aibio.space lists Rallybio Corporation among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Rallybio incorporated?

SEC records list its state or country of incorporation as DE.

What does Rallybio develop?

Rallybio Corporation is a clinical-stage biotechnology company focused on developing therapies for severe and rare diseases. Its lead program, RLYB116, is a once-weekly, small volume, subcutaneously injected inhibitor of complement component 5 (C5), intended for diseases of complement dysregulation.

What is RLYB116 from Rallybio?

RLYB116: Once-weekly subcutaneous C5 inhibitor for complement dysregulation diseases Stage: two Phase 1 trials completed; confirmatory Phase 1 completed in 2025.

What is RLYB332 from Rallybio?

RLYB332: Long-acting matriptase-2 antibody for diseases of iron overload Stage: preclinical development.

What was Rallybio's revenue last year?

$858,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC.

## Investor discussion: Rallybio

Members talk about Rallybio (RLYB). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Rallybio, newest first. Each line links the filing it comes from.

1. 2026-08-06 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1739410/000162828026053880/rlyb-20260630.htm)
2. 2026-07-15 Mergers Reported a merger or acquisition agreement. SEC Form S-4. [Source](https://www.sec.gov/Archives/edgar/data/1739410/000119312526304966/d71655ds4.htm)
3. 2026-05-04 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1739410/000119312526202601/d19625d8k.htm)
4. 2026-03-16 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1739410/000162828026018261/rlyb-20251231.htm)
5. 2026-03-02 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.02,5.01,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1739410/000119312526084444/d108429dex991.htm)
6. 2026-01-29 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1739410/000173941026000010/rlyb-20260126.htm)
7. 2026-01-02 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1739410/000114036126000191/ny20061662x2_def14a.htm)
8. 2025-12-23 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1739410/000114036125046536/ny20061662x1_pre14a.htm)
9. 2025-08-29 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1739410/000119312525192749/d239571d8k.htm)
10. 2025-07-08 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1739410/000173941025000100/rlyb-20250708.htm)
11. 2025-03-13 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1739410/000119312525053960/d891875d424b5.htm)
12. 2025-02-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1739410/000173941025000021/rlyb-20250224.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:RLYB on TradingView](https://www.tradingview.com/symbols/NASDAQ-RLYB/).

## SEC filings and registration

- **SEC name**: Rallybio Corp

- **CIK**: 1739410

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: RLYB (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: <br>Emerging growth company

- **Business address**: 234 CHURCH STREET, NEW HAVEN, CT, 06510

- **Phone**: 203- 859-3820

- **Shares outstanding**: 5,310,499 as of 2026-07-30 (10-Q filed 2026-08-06)

- **Former names**: Rallybio Holdings, LLC

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1739410/000119312526386511/d96849d8k.htm) filed 2026-09-09
- [10-Q](https://www.sec.gov/Archives/edgar/data/1739410/000162828026053880/rlyb-20260630.htm) filed 2026-08-06
- [8-K](https://www.sec.gov/Archives/edgar/data/1739410/000119312526249790/d19106d8k.htm) filed 2026-06-01
- [10-Q](https://www.sec.gov/Archives/edgar/data/1739410/000162828026034580/rlyb-20260331.htm) filed 2026-05-13
- [8-K](https://www.sec.gov/Archives/edgar/data/1739410/000119312526202601/d19625d8k.htm) filed 2026-05-04
- [8-K](https://www.sec.gov/Archives/edgar/data/1739410/000162828026022385/rlyb-20260331.htm) filed 2026-03-31
- [10-K](https://www.sec.gov/Archives/edgar/data/1739410/000162828026018261/rlyb-20251231.htm) filed 2026-03-16
- [8-K](https://www.sec.gov/Archives/edgar/data/1739410/000119312526084444/d108429d8k.htm) filed 2026-03-02

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001739410), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

Rallybio Corporation is a public biotech or pharmaceutical company listed on NASDAQ under the ticker RLYB, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: Rallybio Corporation

- **Ticker**: RLYB

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Biotechnology

- **ISIN**: US75120L2097

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-RLYB/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/rallybio/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Rallybio (RLYB) news: reverse merger and offering", 2026-10-31, https://aibio.space/companies/rallybio/